Replies to post #70997 on Biotech Values

[rkrw]

I don't think when someone bought makes a difference. La Jolla was running out money. For a company with no funding or prospects for funding with low clinical expectations this was an amazing deal for ljpc. Even if it works, I think biomarin paid a lot more than they had to.